FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer t…

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

Expanded indication extends ANKTIVA plus BCG to patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), including those with carcinoma in situ (CIS), with or without papillary tumors, and those with papillary-only tumors

Papillary disease represents approximately 85% of the NMIBC patient population1

This is the first FDA approval to include BCG-unresponsive NMIBC with papillary-only tumors

With this FDA approval, access to ANKTIVA plus BCG expands to include all patients with BCG-unresponsive NMIBC | $IBRX